Welcome to our dedicated page for Ngm Biopharmaceuticals news (Ticker: NGM), a resource for investors and traders seeking the latest updates and insights on Ngm Biopharmaceuticals stock.
NGM Biopharmaceuticals, Inc. (NGM) has described itself as a biotechnology company focused on discovering and developing novel, life-changing medicines, with all product candidates generated by its in-house discovery engine. The NGM Bio news flow reflects this biology-centric strategy across oncology, liver disease and rare conditions, as well as significant corporate developments affecting the former NGM stock listing.
News coverage for NGM Bio includes updates on its solid tumor oncology programs, such as clinical data from the ongoing Phase 1/2 trial of NGM707, a dual ILT2/ILT4 antagonist antibody product candidate, in combination with KEYTRUDA (pembrolizumab) in advanced or metastatic solid tumors. The company has also reported progress on NGM831 and NGM438, antagonist antibody product candidates targeting ILT3 and LAIR1, respectively, in combination with pembrolizumab.
Investors and observers can also find news items detailing NGM Bio’s work in liver and metabolic diseases, including positive Phase 2b results from the ALPINE 4 trial of aldafermin, an engineered FGF19 analog, in patients with compensated cirrhosis due to NASH, and plans to further develop aldafermin for primary sclerosing cholangitis. Additional updates have covered the potential development of NGM120, a GDF15/GFRAL antagonist antibody product candidate, for hyperemesis gravidarum, a rare and serious pregnancy-related condition.
Another important theme in NGM Bio news is corporate and transaction activity. The company announced an Agreement and Plan of Merger with Atlas Neon Parent, Inc. and Atlas Neon Merger Sub, Inc., affiliates of The Column Group, LP, followed by the closing of a cash tender offer and subsequent merger that resulted in NGM Bio becoming a privately held, wholly-owned subsidiary and its common stock ceasing to trade on Nasdaq.
By reviewing the NGM news feed, readers can track historical announcements on clinical data presentations, conference participation, strategic updates on pipeline prioritization, and the steps that led to the going-private transaction. This provides context on how NGM Bio’s scientific programs and corporate structure have evolved over time.
Xaira Therapeutics has appointed Jeff Jonker as President and Chief Operating Officer, reporting to CEO Marc Tessier-Lavigne. Jonker, a biotech industry veteran with over two decades of leadership experience, will help scale Xaira's AI-enabled drug discovery platform and oversee operational functions.
Jonker's experience includes serving as CEO of Belharra Therapeutics and Ambys Medicines, and as President of NGM Biopharmaceuticals (NASDAQ: NGM). At NGM, he expanded the therapeutic pipeline and formed a strategic partnership with Merck. The appointment comes as Xaira advances its AI-driven drug discovery initiatives, recently publishing X‑Atlas/Orion, the largest publicly available genome-wide Perturb‑seq dataset.
Summary not available.
Summary not available.
Summary not available.
Summary not available.
Summary not available.
Summary not available.
Summary not available.
Summary not available.
Summary not available.
